Eye cancer study dispels the theory of nerve activity

Article

Researchers have identified a cell that causes eye cancer, suggesting for the first time that deliberate genetic manipulations may encourage the brain to heal itself.

Researchers have identified a cell that causes eye cancer, suggesting for the first time that deliberate genetic manipulations may encourage the brain to heal itself. The study, published in Cell, has dispelled a long-standing theory about nerve growth and development.

Michael Dyer and colleagues at St Jude Children's Research Hospital, US, found that reducing the activity of the Rb genes in mice retina enables fully differentiated horizontal neurons to multiply while retaining the features of normal horizontal neurons. This demonstrates that retinoblastoma can arise from fully matured horizontal interneurons in the retina and thereby disproves the idea that fully developed nerves cannot multiply like young cells.

Based on these findings, the researchers believe that it may be possible for scientists to induce fully developed neurons to help the brain to heal itself by controlling gene activity in the neurons. This will encourage them to multiply and replace the neurons that were lost as a result of neurodegenerative diseases such as Alzheimer's.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.